HEMANGINI PATEL: Open Payments
NPI 1558761924 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,344 in 54 payments from 11 companies in 2025. Trend: 2023 $429 · 2024 $1,606 · 2025 $1,344
Food & beverage: $1,344
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 11 | $267 |
| UCB, Inc. | 8 | $259 |
| ABBVIE INC. | 10 | $225 |
| Lilly USA, LLC | 9 | $194 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Janssen Biotech, Inc. | 3 | $78 |
| Novartis Pharmaceuticals Corporation | 3 | $78 |
| Arcutis Biotherapeutics, Inc. | 3 | $66 |
| Galderma Laboratories, L.P. | 2 | $45 |
| LEO Pharma Inc. | 1 | $25 |
Products named: OPZELURA, Bimzelx, SKYRIZI, TALTZ, TREMFYA, Zoryve, DUPIXENT, Rhapsido.
Industry payments across CA — which companies pay providers there.
